De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)
De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
Sponsor: Breast International Group
Terminated
Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evaluate the potential solutions to overcome the issues.
Other terminated trials from Breast International Group
- BRCA1 Gene Mutation · Phase PHASE3 · Oct 2021
- Breast Cancer · Phase PHASE3 · Dec 2006
- Breast Cancer · Phase PHASE3
More terminations from Breast International Group
This PHASE2 trial investigates ER-Negative Breast Cancer and HER2-positive Breast Cancer and is currently terminated or withdrawn. Breast International Group leads this study, which shows 13 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Oct 2024 — Jan 2025 [monthly]
Suspended PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
▶ Show 8 earlier versions
-
Oct 2023 — Jul 2024 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jun 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Breast International Group
- Hoffmann-La Roche
- Institut Curie
- International Drug Development Institute
- Jules Bordet Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Aarau, Switzerland , Angers, France , Antwerp, Belgium , Auchenflower, Australia , Avignon, France , Baden, Switzerland , Ballarat, Australia , Basel, Switzerland , Bayonne, France and 64 more locations